Intercept loses chief medical officer months after CEO stepped down Clover raises $230M as COVID-19 vaccine nears phase 3, multivariant prospect gets going Gene editing biotech Beam adds to drug delivery stable with $120M GuideTx buy In Partnership: Commercialization in Canada: Navigating Complex Requirements to Drive Product Success Alexion alums land at complement biotech Kira Pharma as it plots its course through the clinic Chosen wisely: Grail, Quest team up on cancer blood test Altasciences buys WCCT Global, then gets snapped up itself by a pharma VC Sanofi, Regeneron's Libtayo snags lung cancer nod, taking a stab at Keytruda's megablockbuster lead Featured Story | By Ben Adams Dogged by questions over the safety of its approved liver drug Ocaliva and reeling from a rejection for the drug in fatty liver disease, Intercept has been shedding its C-suite. read more |
| |
|---|
|
Top Stories By Nick Paul Taylor Clover Biopharmaceuticals has raised $230 million to take a COVID-19 vaccine candidate into a phase 2/3 clinical trial. The series C positions the Chinese biotech to validate the efficacy of its vaccine and gear up to manufacture hundreds of millions of doses this year. read more By Amirah Al Idrus Not all gene editing treatments are created equal—that’s why Beam Therapeutics started out with multiple technologies from the likes of MIT, Harvard, the Broad Institute and Editas Medicine. Now, it’s adding another arrow to its drug delivery quiver with its $120 million acquisition of GuideTx, a Georgia Tech spinout. read more In Partnership With: AmerisourceBergen The Canadian pharmaceutical market, which is among the 10 largest worldwide, has long been viewed as a top-tier launch destination. read more By Amirah Al Idrus As Kira Pharma shepherds two more programs toward the clinic, the complement-focused biotech is bolstering its leadership team with a trio of biopharma veterans, including Dana Zhang, formerlythe general manager for Greater China at Alexion, where she led the approval of Soliris in China, Taiwan and Hong Kong. read more By Conor Hale In a gift to your headline writer, Grail has tapped testing giant Quest Diagnostics to help roll out its upcoming multi-cancer blood test. read more By Ben Adams Hot on the heels of a deal that saw Canadian CRO Altasciences buy out WCCT Global, the company was then acquired itself by Novo Holdings. read more By Angus Liu Sanofi and Regeneron’s immuno-oncology med Libtayo is on a roll with its second FDA approval in just two weeks. The latest nod pushes the PD-1 inhibitor out of its skin cancer comfort zone and into the competitive—and lucrative—lung cancer market where Merck & Co.’s Keytruda reigns supreme. read more Enrollment Showcase | Sponsored by: University of Florida College of Pharmacy Learn about the Top 5-Ranked UF College of Pharmacy’s online graduate programs in pharmaceutical outcomes & policy. Select from five specializations, including the new pharmaceutical value assessment & communication option. Over half of graduates progress to a new role within one year. Register now. |
| |
|---|
|
Resources Sponsored By: Oracle Health Sciences New research indicates an accelerated adoption of decentralized clinical trials due to COVID-19. Sponsored By: Within3 We enable virtual work — offering over-time sessions where participants are more focused, insights are more diverse and business goals are met. Sponsored By: Medidata, a Dassault Systèmes company 8 parameters to optimize your “Path to Virtualization” across site- and patient-centric capabilities in this Sponsor Edition eBook. Sponsored By: LabVantage Solutions Uncover the real impact of “digital transformation” with practical advice to help you plan your own transformative journey to a harmonized digital ecosystem. Sponsored By: Acorn AI, a Medidata Company Acorn AI has developed a flexible and scalable Commercial Data Model that provides pharmaceutical companies with the data-driven insights required to respond to the industry’s ever-changing landscape. Download the whitepaper to learn how Acorn AI’s intuitive data model enables launch success and more. Sponsored By: Outer Edge Technology Criminals Are Actively Exploiting The CV-19 Pandemic To Gain Entry To Enterprise Networks. Don’t Let Your Company Become A Cybercrime Statistic -- Make These Cost-Effective IT Changes Now! Sponsored by: Cytiva It’s an exciting time to pioneer what could be a life-changing medicine. Clear the path to the clinic with pro tips and expert insights from industry leaders. Sponsored by: Cytiva A one-stop hub for Cytiva resources to support process development and manufacturing of your novel molecule Sponsored by: Catalent Autologous cell therapies have seen propelled growth since 2017, with the spotlight on the first FDA approval of a chimeric antigen receptor (CAR) T cell immunotherapy, Kymriah® (tisagenlecleucel), for the treatment of relapsed/refractory B-cell acute lymphoblastic leukemia. Sponsored by: Premier Research Browse the latest learnings and insights from our clinical development professionals. Sponsored by: Catalent Learn about drug product process development challenges and risks, the difference between innovator and biosimilar drug product process development, and more during the drug product process development phase. Sponsored by: Catalent Get insights on key considerations for a successful tech transfer process for manufacturing a biologic drug product, including a case study on overcoming challenges in a process transfer for a sterile diluent. Sponsored by: Catalent In a BioPharma Dive industry survey, planning and forecasting were identified as top concerns for trial sponsors. In response to this need, the CSM team at Catalent has developed a methodology for identifying, evaluating, and proactively managing the inherent risks involved in clinical trial supply chain management. Sponsored by: Catalent Learn how to drive excellence within the forecasting process and utilize forecasting throughout the clinical study to better plan clinical supply budgets and project timelines. Explore how to identify potential supply-related issues before they can negatively impact your study. For non-scientists. Learn the science driving biopharma. February 25-26, 2021 | 9 a.m. EST / 6 a.m. PST Learn what it takes to get a drug developed and approved March 9-10, 2021 | 9 a.m. EST / 6 a.m. PST BD&L Summit for Life Sciences March 9–10, 2021 | Virtual Event Learn the science driving biopharma. Specific for the non-scientist. March 18-19, 2021 | 12 p.m. EST / 9 a.m. PST Learn what it takes to get a drug developed and approved April 13-14, 2021 | 12 p.m. EST / 9 a.m. PST
Learn the science driving biopharma. Specific for the non-scientist. April 20-21, 2021 | 12 p.m. EST / 9:00 a.m. PST Learn what it takes to get a drug developed and approved April 22-23, 2021 | 9:00 a.m. EST / 6 a.m. PST Learn the science driving biopharma. Specific for the non-scientist. May 6-7, 2021 | 9:00 a.m. EST / 6 a.m. PST Vaccines, cell and gene therapy, therapeutic antibodies and RNA drugs May 20-21, 2021 | 12 p.m. EST / 9 a.m. PST Learn what it takes to get a drug developed and approved June 2-3, 2021 | 9 a.m EST / 6 a.m.PST Vaccines, cell and gene therapy, antibodies, and RNA-based drugs June 10-11, 2021 | 9 a.m. EST / 6 a.m. PST Drug Development Boot Camp® 2021 Onsite and VIRTUAL in real time November 17-18, 2021 | Register now! Pre-Boot Camp preparation is now available. | 